secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001558370-24-004700
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences reports FY2023 revenue of $8.7M, down 22.8% as GLP-1 drugs pressure bariatric market
--------------------------------------------------------------------------------

- FY2023 revenue $8.7M, down 22.8% YoY; Lap-Band unit sales fell 26.8% due to GLP-1 competition.
- Gross profit $5.5M (63.9% margin vs 60.5% in 2022); sales & marketing expenses cut 46.8% to $7.5M.
- Cash $4.5M and debt-free; expects 2024 operating expenses to decrease >50% vs 2023 via further RIF.
- Received FDA approval for Lap-Band 2.0 FLEX in Dec 2023; first surgeries completed in Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/0001558370-24-004700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/rsls-20240401x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer